Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies

Commentary
Video

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC discussed her talk on preparing for gene therapy administration.

“It is hard to understand the gravity of these medicines, because we always focus on such positive outcomes. But there's a dark side to it. And it's scary. There are side effects and it's hard to sometimes convey that. So, one of the challenges is that we have is to make sure that the patients understand what they're signing up for, that there is a risk of death, that there is a risk of other serious injuries and that they can be admitted to the hospital for some very serious potential side effects."

As gene therapies enter the clinical space and become more common, it has become paramount to examine and standardize the logistics of delivering gene therapies, including interdepartmental collaboration in centers delivering these therapies as well as informed consent and preparing patients and families for what gene therapy entails.

Leigh Ramos-Platt, MD, Medical Director, Muscular Dystrophy Association Neuromuscular Clinic and attending physician, Division of Neurology, Children’s Hospital Los Angeles, and Clinical Professor of Neurology and Pediatrics, Keck School of Medicine, University of Southern California (USC), gave a talk around this topic at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 3-6, in Orlando, Florida.

CGTLive® spoke with Ramos-Platt to learn more about the talk and the greater session on post-gene therapy monitoring. She stressed the importance of making sure that patients and families of all backgrounds be able to access these lifesaving therapies, but are also adequately prepared for them. She also shared that across talks in the session, communication was most often identified as the most important factor in the post-gene therapy time period.

REFERENCE
Ramos-Platt L. DMD Gene Therapy Day Of: Institutional and Patient/Family Readiness- When We Were Not a Trial Site. Presented at: 2024 MDA Clinical and Scientific Conference; March 3-6; Orlando, FL.
Related Videos
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Marcus Conant, MD, on More Research Needed With HIV Therapies
© 2024 MJH Life Sciences

All rights reserved.